# Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer

> **NCT00063388** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 66 (actual)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Cetuximab

## Key facts

- **NCT ID:** NCT00063388
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** 2005-06
- **Final completion:** 2005-06
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2010-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00063388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00063388, "Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00063388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*